Comparative Pharmacology
Head-to-head clinical analysis: AUGMENTIN 125 versus STAPHCILLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUGMENTIN 125 versus STAPHCILLIN.
AUGMENTIN '125' vs STAPHCILLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin activation. Clavulanate is a beta-lactamase inhibitor that irreversibly binds to and inactivates beta-lactamases, preventing hydrolysis of amoxicillin.
Semisynthetic penicillin; inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes.
One AUGMENTIN '125' tablet (amoxicillin 125 mg, clavulanate 31.25 mg) orally every 8 hours for mild to moderate infections.
1-2 g IV every 4-6 hours.
None Documented
None Documented
Amoxicillin: 1.0-1.3 hours (prolonged in renal impairment; up to 7-20 hours in anuria). Clavulanate: 0.9-1.2 hours (increased in renal impairment).
0.5-1 hour in adults with normal renal function; prolonged to 2-4 hours in renal impairment. Infants: 1-2 hours.
Amoxicillin: ~50-70% excreted unchanged in urine via glomerular filtration and tubular secretion; clavulanate: ~30-50% excreted unchanged in urine. Small amounts eliminated in bile and feces.
Primarily renal (70-90% as unchanged drug via glomerular filtration and tubular secretion); minor biliary excretion (<5%) and fecal elimination (<1%).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic